AbbVie
VC Fund
Chicago, United States
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVieemploys approximately 21,000 people worldwide and markets medicines in more than 170 countries.
- Total investments:
- 70
- Last investment:
- Lead investor:
- 23%
Last updated:
For AI agents: llms.txt
Industries AbbVie invests in
Stages AbbVie invests in
Countries AbbVie invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Round size
- Seed
- $4M–$42M
- Grant
- $3.5M–$50M
- Series A
- $7M–$81M
Investment Focus
Industry
- Biotechnology 41 (59%)
- Health Care 32 (46%)
- Medical 19 (27%)
- Therapeutics 16 (23%)
- Pharmaceutical 16 (23%)
Stage
- Series A 24 (34%)
- Grant 13 (19%)
- Seed 7 (10%)
- Series B 6 (9%)
- Venture - Series Unknown 5 (7%)
Country
- United States 45 (64%)
- United Kingdom 2 (3%)
- China 1 (1%)
- Italy 1 (1%)
- France 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Melissa A. Walsh
Vice President, State Government Affairs
|
Vice President, State Government Affairs | Total investments: 0 | Find email | |
Will Haines
Field Director - Oncology Medical Science Liaisons
|
Field Director - Oncology Medical Science Liaisons | Total investments: 0 | Find email | |
Amanda Graber Rosenberg
Global Communications Strategy & Planning
|
Global Communications Strategy & Planning | Total investments: 0 | Find email | |
Arminda Montero
Program Manager, Global Supply Chain QA
|
Program Manager, Global Supply Chain QA | Total investments: 0 | Find email | |
Henry Gosebruch
EVP and Chief Strategy Officer
|
EVP and Chief Strategy Officer | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Cloverleaf Bio develops an RNA therapeutic platform for oncology. | $33M / Seed / Sep 08, 2026 | ||
| ndLyz Therapeutics, Inc. is developing disease-modifying therapeutics which restore endo-lysosomal function and abrogate neurodegeneration in Parkinson’s disease (PD) and other dementias. | $17.3M / Seed / Apr 23, 2026 | ||
| DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells. | $42.3M / Seed / Dec 11, 2025 | ||
| Zag Bio™ has discovered a novel approach to create thymus-targeted medicines to treat and prevent autoimmune diseases by restoring central immune tolerance. Zag Bio designs bifunctional antibodies that deliver self-antigens to antigen-presenting cells in the thymus to harness the body’s natural process for training immune cells to recognize andtolerate self, halting or preventing autoimmune attacks on the body’s own tissues. Zag Bio’s pipeline includes ZAG-101, its lead program for Type 1 diabetes, as well as discovery programs for thymus-targeted therapies to address other autoimmune diseases and help patients and their caregivers. Located in Cambridge, Massachusetts, Zag Bio’s team includes experienced experts in thymus biology, autoimmune diseases and innovative drug development.Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases. | $80M / Series A / Oct 28, 2025 | ||
| Syndeio Biosciences is a clinical-stage biotechnology company focused on developing therapies to restore and enhance synaptic health in central nervous system (CNS) disorders. | $90M / Venture - Series Unknown / May 27, 2025 | ||
| ThirtyFiveBio is a biotechnology agency | Venture - Series Unknown / Apr 15, 2025 | ||
| Cephagenix focuses on identifying and developing new, effective migraine therapies. | $9.3M / Seed / Jan 16, 2025 | ||
| Light Horse Therapeutics is the gene editing applied to small-molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases. Its advanced platform identifies cryptic chemically accessible functional domains within targets that are critical in disease biology. Our initial focus addresseshigh-value, historically challenging oncology targets with the opportunity to apply the technology to other therapeutic areas in the future. | $62M / Series A / Jan 09, 2025 | ||
| Soufflé Therapeutics is a biotechnology company specializing in the development of nucleic acid medicines designed for precise delivery and targeting of disease-causing cells. The company's mission is to create potent, precise, and safe medicines that can be tailored for a broad range of diseases by leveraging breakthroughs in genetic medicineand drug delivery technology. | $200M / Series A / Jan 01, 2025 | ||
| Oisin Biotechnologies is a platform drug development company focused on creating drugs to combat a variety of age-related diseases. It is developing a highly precise, patent-pending, DNA-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces the negative effects of aging pathologies and alsoextends the median lifespan and survival.Oisin Biotechnologies was founded in 2014 and is headquartered in Seattle, Washington. | $15M / Series A / Jul 24, 2024 | ||
| See all 70 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does AbbVie invest in?
AbbVie invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Grant stage. Most of the 70 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is AbbVie's check size?
AbbVie typically joins rounds of $4M–$42M at Seed, $3.5M–$50M at Grant and $7M–$81M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds AbbVie participates in.
How do I contact AbbVie?
Public channels for AbbVie include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at AbbVie?
The team at AbbVie includes Melissa A. Walsh (Vice President, State Government Affairs), Will Haines (Field Director - Oncology Medical Science Liaisons) and Amanda Graber Rosenberg (Global Communications Strategy & Planning), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
